Jaguar Health, Inc. (JAGX)
JAGX moved a median of -0.38% 30 minutes after news, and -0.74% by the close. How JAGX actually reacts to news — the realized, point-in-time move the market made, measured across 442 labeled events over the last three years with zero look-ahead.
JAGX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.05% | 41% | 432 |
| 30-min | -0.38% | 41% | 441 |
| 60-min | -0.55% | 42% | 441 |
| to close | -0.74% | 43% | 438 |
| Middle 50% of JAGX reactions | -3.37% to +1.15% |
|---|---|
| Median reaction (30-min) | -0.38% |
| Measured reactions | 442 |
Half of all Jaguar Health, Inc. news events land between -3.37% and +1.15% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when JAGX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to JAGX's baseline. Nothing else.
Recent JAGX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend | Press release | ACCESS Newswire | +0.00% | — | |
| Form DEF 14A Jaguar Health, Inc. For: Nov 06 | SEC filing · Form DEF | SEC EDGAR | +0.44% | +5.04% | |
| Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi | Press release | ACCESS Newswire | -3.21% | -14.33% | |
| Form 8-K Jaguar Health, Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -0.70% | +10.77% | |
| Jaguar Health Announces a Special Stock Dividend | Press release | ACCESS Newswire | -0.70% | +10.77% | |
| Form PRER14A Jaguar Health, Inc. | SEC filing · Form PRER14A | SEC EDGAR | +1.42% | -10.71% | |
| Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting | Press release | ACCESS Newswire | -3.54% | -0.93% | |
| Form 8-K Jaguar Health, Inc. For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | -1.43% | -13.13% | |
| Form 8-K Jaguar Health, Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +8.47% | -15.29% | |
| Form 8-K Jaguar Health, Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +1.11% | -0.56% | |
| Jaguar Health Receives Fee Waivers from FDA | Press release | ACCESS Newswire | -2.22% | — | |
| Form 8-K Jaguar Health, Inc. For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -2.22% | — | |
| Form PRE 14A Jaguar Health, Inc. For: Oct 23 | SEC filing · Form PRE | SEC EDGAR | -4.64% | -6.97% | |
| Form 8-K Jaguar Health, Inc. For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | -2.22% | -0.31% | |
| Form 8-K Jaguar Health, Inc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -3.48% | -25.13% | |
| Jaguar Health, Inc. Announces Reverse Stock Split | Press release | ACCESS Newswire | -3.48% | -25.13% | |
| All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF) | Press release | ACCESS Newswire | -7.33% | -13.05% | |
| Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs | Press release | ACCESS Newswire | -5.08% | -18.09% | |
| Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) | Press release | ACCESS Newswire | -2.87% | -11.85% | |
| Form 8-K Jaguar Health, Inc. For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | -5.08% | -18.09% | |
| Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs | Press release | ACCESS Newswire | -3.01% | -1.14% | |
| Form 10-Q Jaguar Health, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | -4.20% | |
| Form 8-K Jaguar Health, Inc. For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | -4.56% | +0.40% | |
| Jaguar Health Reports Second Quarter 2026 Financials | Press release | ACCESS Newswire | -4.56% | +0.40% | |
| Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates | Press release | ACCESS Newswire | -0.76% | +14.54% | |
| Form EFFECT Jaguar Health, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -2.50% | -2.34% | |
| Form NT 10-Q Jaguar Health, Inc. For: Jun 30 | SEC filing · Form NT | SEC EDGAR | -2.50% | -2.34% | |
| Form POS AM Jaguar Health, Inc. | SEC filing · Form POS | SEC EDGAR | +0.38% | -4.83% | |
| Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 | Press release | ACCESS Newswire | +0.81% | +1.44% | |
| Form DEF 14A Jaguar Health, Inc. For: Sep 04 | SEC filing · Form DEF | SEC EDGAR | +1.25% | +1.25% | |
| Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog | Press release | ACCESS Newswire | -0.20% | -0.77% | |
| Form EFFECT Jaguar Health, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.70% | +3.07% | |
| Form PRE 14A Jaguar Health, Inc. For: Sep 04 | SEC filing · Form PRE | SEC EDGAR | -0.70% | +3.07% | |
| Form S-1/A Jaguar Health, Inc. | SEC filing · Form S-1 | SEC EDGAR | +4.93% | -1.85% | |
| Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID) | Press release | ACCESS Newswire | +2.93% | +2.31% | |
| Form S-1 Jaguar Health, Inc. | SEC filing · Form S-1 | SEC EDGAR | -1.54% | -31.54% | |
| Form 8-K Jaguar Health, Inc. For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | +0.23% | -8.45% | |
| Form 8-K Jaguar Health, Inc. For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | -6.33% | |
| Form D Jaguar Health, Inc. | SEC filing · Form D | SEC EDGAR | -1.72% | +4.47% | |
| Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) | Press release | ACCESS Newswire | — | +2.04% | |
| Form 8-K Jaguar Health, Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +3.38% | +2.63% | |
| Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend | Press release | ACCESS Newswire | +3.38% | +2.63% | |
| Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs | Press release | ACCESS Newswire | -2.70% | +1.19% | |
| Form 8-K Jaguar Health, Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +3.51% | +14.47% | |
| Form 8-K/A Jaguar Health, Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | -2.70% | +1.19% | |
| Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program | Press release | ACCESS Newswire | +3.51% | +14.47% | |
| Form 8-K Jaguar Health, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +3.51% | +14.47% | |
| Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention | Press release | ACCESS Newswire | -0.84% | -5.86% | |
| Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases | Press release | ACCESS Newswire | -2.88% | -5.28% | |
| Form 8-K Jaguar Health, Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | -5.46% | +2.36% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the JAGX section they belong to.
Where else JAGX is measured.
JAGX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CareDx, Inc. (CDNA) | 443 | -0.11% | 47% |
| Arvinas, Inc. (ARVN) | 442 | -0.26% | 42% |
| BOVIE MEDICAL (BVX) | 441 | 0.00% | 46% |
| Catalyst Pharmaceuticals, Inc. (CPRX) | 441 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Jaguar Health, Inc.'s median reaction calculated?
Every labeled JAGX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 442 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of JAGX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does JAGX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.